Twin Focus Capital Partners’s Pacira BioSciences PCRX Stock Holding History

Twin Focus Capital Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,516	Closed	-$222K	–	115
2018 Q3	$222K	Buy	+4,516	New	+$195K	0.11%	91
2018 Q1	–	Sell	-4,516	Closed	-$206K	–	108
2017 Q4	$206K	Buy	+4,516	New	+$179K	0.1%	90
2017 Q3	–	Sell	-4,516	Closed	-$215K	–	101
2017 Q2	$215K	Hold	4,516	–	–	0.12%	86
2017 Q1	$206K	Sell	4,516 -2,300	-34%	-$99.4K	0.12%	83
2016 Q4	$220K	Hold	6,816	–	–	0.14%	70
2016 Q3	$233K	Hold	6,816	–	–	0.16%	67
2016 Q2	$230K	Hold	6,816	–	–	0.18%	66
2016 Q1	$361K	Hold	6,816	–	–	0.34%	50
2015 Q4	$523K	Hold	6,816	–	–	0.53%	42
2015 Q3	$280K	Hold	6,816	–	–	0.36%	52
2015 Q2	$482K	Hold	6,816	–	–	0.54%	38
2015 Q1	$606K	Hold	6,816	–	–	0.48%	31
2014 Q4	$604K	Hold	6,816	–	–	0.7%	30
2014 Q3	$661K	Sell	6,816 -3,407	-33%	-$331K	0.65%	25
2014 Q2	$939K	Hold	10,223	–	–	1.06%	18
2014 Q1	$716K	Buy	10,223 +242	+2%	+$16.5K	0.85%	22
2013 Q4	$574K	Buy	+9,981	New	+$525K	0.57%	30

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Twin Focus Capital Partners's PCRX Position: Q4 2018 in Review

Twin Focus Capital Partners sold out of Pacira BioSciences (PCRX) in Q4 2018, closing a stake of 4,516 shares — an estimated $222K sold.

Twin Focus Capital Partners first reported a position in PCRX in Q4 2013 and held it in 17 quarters. The position peaked at $939K in Q2 2014. 208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

Twin Focus Capital Partners reported no remaining Pacira BioSciences position as of Q4 2018 after selling out during the quarter.
Twin Focus Capital Partners sold 4,516 Pacira BioSciences shares in Q4 2018, an estimated $222K.
Twin Focus Capital Partners first reported a position in Pacira BioSciences in Q4 2013 and held it in 17 quarters.
Twin Focus Capital Partners's Pacira BioSciences position peaked at $939K in Q2 2014.
208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on Twin Focus Capital Partners's 13F filing for Q4 2018, filed 13 Feb 2019.